ERLYAND®
APALUTAMIDE
AUSTRALIAN PRODUCT INFORMATION

1. NAME OF THE MEDICINE
Apalutamide

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
ERLYAND 60 mg tablets contain 60 mg of apalutamide.
For a full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM
ERLYAND is supplied as slightly yellowish green to greyish green, oblong-shaped, film-coated tablets, debossed with “AR 60” on one side.

4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
ERLYAND (apalutamide) is indicated for the treatment of patients with:
- metastatic castration-sensitive prostate cancer (mCSPC) or
- non-metastatic, castration-resistant prostate cancer (nmCRPC).

4.2 DOSE AND METHOD OF ADMINISTRATION
Dose
The recommended dose of ERLYAND is 240 mg (four 60 mg tablets) administered orally once daily.
Patients should concurrently receive a gonadotropin-releasing hormone (GnRH) analogue, unless they have had a bilateral orchiectomy.

Method of administration
ERLYAND tablets should be swallowed whole and can be taken with or without food.
If the patient misses a dose, it should be taken as soon as possible on the same day with a return to the normal schedule on the following day. The patient should not take extra tablets to make up the missed dose.
Dosage adjustment
If a patient experiences a ≥ Grade 3 toxicity or an intolerable adverse effect, hold dosing until symptoms improve to ≤ Grade 1 or original grade, then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted.

4.3 CONTRAINDICATIONS
ERLYAND is contraindicated in women who are or may become pregnant, see section 4.6 Use in pregnancy.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Ischaemic cardiovascular events and ischaemic cerebrovascular disorders
Ischaemic cardiovascular events and ischaemic cerebrovascular disorders, including events leading to death, occurred in patients receiving ERLYAND. Monitor for signs and symptoms of ischaemic heart disease. Optimise management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidaemia. Consider discontinuation of ERLYAND for Grade 3 and 4 events.

In the SPARTAN study, with a median exposure of 32.9 months for ERLYAND and 11.5 months for placebo, ischaemic cerebrovascular disorders occurred in 4% of patients treated with ERLYAND and 1% of patients treated with placebo (see 4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS). In the TITAN study, ischaemic cerebrovascular disorders occurred in a similar proportion of patients in the ERLYAND (1.5%) and placebo (1.5%) groups. Across the SPARTAN and TITAN studies, 2 patients (0.2%) treated with ERLYAND and no patients treated with placebo died from an ischaemic cerebrovascular disorder.

Patients with clinically significant cardiovascular disease in the past 6 months including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischaemic attacks), or clinically significant ventricular arrhythmias were excluded from the clinical studies (SPARTAN and TITAN). Therefore, the safety of apalutamide in these patients has not been established.

Fractures
Fractures occurred in patients receiving ERLYAND. Evaluate patients for fracture risk. Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone-targeted agents. See section 4.8 Description of selected adverse events.

Falls
Falls (including events leading to death) occurred in patients receiving ERLYAND with increased frequency in the elderly. Evaluate patients for fall risk. See section 4.8 Description of selected adverse events.

Seizure
Seizure occurred in patients receiving ERLYAND. Permanently discontinue ERLYAND in patients who develop a seizure during treatment. It is unknown whether anti-epileptic medications will prevent seizures with ERLYAND and there is no clinical experience in re-administering ERLYAND to patients who experienced a seizure. Advise patients of the risk of developing a seizure while receiving ERLYAND and of engaging in any activity where sudden loss of consciousness could cause harm to themselves or others. See section 4.7 Effects on ability to drive and use machines and section 4.8 Description of selected adverse events.
Hypothyroidism
Hypothyroidism occurred in patients receiving ERLYAND, more commonly in patients who were already receiving thyroid replacement therapy. Initiation or adjustment of thyroid replacement therapy may be required. As levothyroxine exposure may be reduced when it is co-administered with apalutamide, evaluate for loss of levothyroxine efficacy and need for dose adjustment. See sections 4.5 Effects of ERLYAND on other medicines and section 4.8 Description of selected adverse events.

QT interval prolongation
In patients with a history of QT prolongation, who are taking concomitant medications that may prolong the QT interval, or who have other risk factors for torsades de pointes, consider electrocardiogram (ECG) and electrolyte monitoring. See section 5.1 Pharmacodynamic effects.

Use in hepatic impairment
ERLYAND has not been studied in patients with severe hepatic impairment (Child-Pugh class C), see section 5.2 Pharmacokinetic properties - Special populations.

Use in renal impairment
ERLYAND has not been studied in patients with severe renal impairment or end-stage renal disease (eGFR ≤ 29 mL/min/1.73m²), see section 5.2 Pharmacokinetic properties - Special populations.

Use in the elderly
Of the 1327 patients who received ERLYAND in clinical studies, 19% of patients were less than 65 years of age, 41% of patients were 65 to 74 years, and 40% were 75 years and over. Adverse events of all categories (including events that led to discontinuation, serious, severe (Grade 3 or 4) and fatal events) and deaths occurred more frequently in the oldest age group (75 years and over) compared to the younger age groups (≤ 65 years and 65 to 74 years). No overall differences in effectiveness between older patients and younger patients were observed, and age had no significant effect on pharmacokinetics (see section 5.2 Special populations).

Paediatric use
The safety and efficacy of ERLYAND in patients aged less than 18 years have not been established. No data are available.

Effects on laboratory tests
See section 4.8 Adverse effects.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Effects of other medicines on ERLYAND

CYP2C8 inhibitors
Apalutamide C_max decreased by 21% while AUC increased by 68% following co-administration of ERLYAND as a 240 mg single dose with gemfibrozil (a strong CYP2C8 inhibitor). Gemfibrozil is predicted to increase the steady-state apalutamide C_max by 32% and AUC by 44%. For the active moieties (sum of unbound apalutamide plus the potency-adjusted unbound N-desmethyl apalutamide), the predicted steady-state C_max increased by 19% and AUC by 23%.
No initial dose adjustment is necessary however, reduce the ERLYAND dose based on tolerability [see section 4.2 Adverse effects]. Mild or moderate inhibitors of CYP2C8 are not expected to affect the exposure of apalutamide.

**CYP3A4 inhibitors**

Apalutamide $C_{\text{max}}$ decreased by 22% while AUC was similar following co-administration of ERLYAND as a 240 mg single dose with itraconazole (a strong CYP3A4 inhibitor). Ketoconazole (a strong CYP3A4 inhibitor) is predicted to increase the steady-state apalutamide $C_{\text{max}}$ by 38% and AUC by 51%. For the active moieties, the predicted steady-state $C_{\text{max}}$ increased by 23% and AUC by 28%.

No initial dose adjustment is necessary however, reduce the ERLYAND dose based on tolerability (see section 4.2 Adverse effects). Mild or moderate inhibitors of CYP3A4 are not expected to affect the exposure of apalutamide.

**CYP3A4/CYP2C8 inducers**

Rifampin (a strong CYP3A4 and moderate CYP2C8 inducer) is predicted to decrease the steady-state apalutamide $C_{\text{max}}$ by 25% and AUC by 34%. For the active moieties, the predicted steady-state $C_{\text{max}}$ decreased by 15% and AUC by 19%.

**Acid lowering agents**

Apalutamide is not ionisable under relevant physiological pH conditions, therefore acid lowering agents (e.g. proton pump inhibitors, $H_2$-receptor antagonists, antacids) are not expected to affect the solubility and bioavailability of apalutamide.

**Medications that affect transporters**

*In vitro*, apalutamide and its N-desmethyl metabolite are substrates for P-gp but not BCRP, OATP1B1, and OATP1B3. Because apalutamide is completely absorbed after oral administration, P-gp does not limit the absorption of apalutamide and therefore, inhibition or induction of P-gp is not expected to affect the bioavailability of apalutamide.

**Effects of ERLYAND on other medicines**

**Effect of ERLYAND on drug metabolising enzymes**

**CYP enzymes**

*In vitro* studies showed that apalutamide and N-desmethyl apalutamide are moderate to strong CYP3A4 and CYP2B6 inducers, are moderate inhibitors of CYP2B6 and CYP2C8, and weak inhibitors of CYP2C9, CYP2C19, and CYP3A4. Apalutamide and N-desmethyl apalutamide do not affect CYP1A2 and CYP2D6 at therapeutically relevant concentrations.

In humans, ERLYAND is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9. Co-administration of ERLYAND with single oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of midazolam (a CYP3A4 substrate), 85% decrease in the AUC of omeprazole (a CYP2C19 substrate), and 46% decrease in the AUC of S-warfarin (a CYP2C9 substrate). ERLYAND did not cause clinically meaningful changes in exposure to pioglitazone (a CYP2C8 substrate).

Concomitant use of ERLYAND with medications that are primarily metabolised by CYP3A4, CYP2C19, or CYP2C9 can result in lower exposure to these medications. Substitution for these medications is recommended when possible or evaluate for loss of efficacy if medication is continued. If given with warfarin, monitor International Normalised Ratio (INR) during ERLYAND treatment.

**UGT**

Apalutamide may induce UDP-glucuronosyl transferase (UGT).
Concomitant administration of ERLYAND with medications that are substrates of UGT can result in lower exposure to these medications. Use caution if substrates of UGT must be co-administered with ERLYAND and evaluate for loss of efficacy (see Section 4.4 Hypothyroidism).

**Effect of apalutamide on drug transporters**

**P-gp, BCRP and OATP1B1**

Apalutamide was shown to be a weak inducer of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. Co-administration of ERLYAND with single oral doses of transporter substrates resulted in a 30% decrease in the AUC of fexofenadine (a P-gp substrate) and 41% decrease in the AUC of rosuvastatin (a BCRP/OATP1B1 substrate) but had no impact on C_{max}.

Concomitant use of ERLYAND with medications that are substrates of P-gp, BCRP, or OATP1B1 can result in lower exposure of these medications. Use caution if substrates of P-gp, BCRP or OATP1B1 must be co-administered with ERLYAND and evaluate for loss of efficacy if medication is continued.

**OCT2, OAT1, OAT3 and MATEs**

*In vitro*, apalutamide and N-desmethyl apalutamide inhibit organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3) and multidrug and toxin extrusions (MATEs), and do not inhibit organic anion transporter 1. Apalutamide is not predicted to cause clinically significant changes in exposure to OAT3 substrates.

**Gonadotropin-releasing hormone (GnRH) analogue**

In subjects with mCSPC receiving leuprolide acetate (a GnRH analogue), co-administration of apalutamide had no apparent effect on the steady-state exposure of leuprolide.

### 4.6 FERTILITY, PREGNANCY AND LACTATION

**Effects on fertility**

Based on animal studies, apalutamide may impair fertility in males of reproductive potential.

Male fertility is likely to be impaired by treatment with apalutamide based on findings in repeat-dose toxicology studies which were consistent with the pharmacological activity of apalutamide. In repeat-dose toxicity studies in male rats (up to 26 weeks) and dogs (up to 36 weeks), atrophy, aspermatia/hypospermatia, degeneration and/or hyperplasia or hypertrophy in the reproductive system were observed at ≥ 25 mg/kg/day in rats (0.5 times the human exposure based on AUC) and ≥ 2.5 mg/kg/day in dogs (0.5 times the human exposure based on AUC).

In a fertility study in male rats, a decrease in sperm concentration and motility, copulation and fertility rates (upon pairing with untreated females) along with reduced weights of the secondary sex glands and epididymis were observed following 4 weeks of dosing at ≥ 25 mg/kg/day (0.5 times the human exposure based on AUC). Effects on male rats were reversible after 8 weeks from the last apalutamide administration.

**Use in pregnancy**

**Category D**

ERLYAND is contraindicated in women who are or may become pregnant. Based on its mechanism of action, ERLYAND may cause fetal harm when administered during pregnancy. There are no data available with the use of ERLYAND during pregnancy in humans.

ERLYAND may be harmful to a developing fetus. Patients having sex with female partners of reproductive potential should use a condom along with another highly effective contraceptive method during treatment and for 3 months after the last dose of ERLYAND.
Animal embryofetal development studies have not been conducted with ERLYAND.

Use in lactation

ERLYAND is not indicated for use in females. There are no data on the presence of apalutamide or its metabolites in human milk, the effect on the breastfed infant, or the effect on milk production.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects of ERLYAND on the ability to drive or use machines have been performed. Patients with a history of seizures or other predisposing factors should be advised of the risk of driving or operating machines (see section 4.4 Special warnings and precautions for use - Seizure).

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The most common adverse reactions (≥10%) that occurred more frequently in ERLYAND-treated patients (≥2% over placebo) in two randomised clinical trials (TITAN and SPARTAN) were fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhoea, and fracture.

TITAN and SPARTAN were double-blind, placebo-controlled, multi-centre clinical studies in which patients with mCSPC (TITAN) or nmCRPC (SPARTAN) were randomised (1:1 and 2:1, respectively) to receive either ERLYAND 240 mg daily or placebo. All patients received a concomitant gonadotropin-releasing hormone (GnRH) analog or had prior bilateral orchiectomy.

The median duration of exposure in TITAN was 20 months (range: 0 to 34 months) in patients who received ERLYAND and 18 months (range: 0.1 to 34 months) in patients who received placebo.

The median duration of exposure in SPARTAN was 16.9 months (range: 0.1 to 42 months) in patients who received ERLYAND and 11.2 months (range: 0.1 to 37 months) in patients who received placebo.

In TITAN, ten patients (2%) who were treated with ERLYAND died from adverse reactions. The reasons for death were ischaemic cardiovascular events (n=3), acute kidney injury (n=2), cardiorespiratory arrest (n=1), sudden cardiac death (n=1), respiratory failure (n=1), cerebrovascular accident (n=1), and large intestinal ulcer perforation (n=1). ERLYAND was discontinued due to adverse reactions in 8% of patients, most commonly from rash (2%). Adverse reactions leading to dose interruption or reduction of ERLYAND occurred in 23% of patients; the most frequent (>1%) were rash, fatigue, and hypertension. Serious adverse reactions occurred in 20% of ERLYAND-treated patients and 20% in patients receiving placebo.

In SPARTAN, 8 patients (1%) who were treated with ERLYAND died from adverse reactions. The reasons for death were infection (n=4), myocardial infarction (n=3), and cerebral haemorrhage (n=1). One patient (0.3%) treated with placebo died from an adverse reaction of cardiopulmonary arrest (n=1). ERLYAND was discontinued due to adverse reactions in 11% of patients, most commonly from rash (3%). Adverse reactions leading to dose interruption or reduction of ERLYAND occurred in 33% of patients; the most common (>1%) were rash, diarrhoea, fatigue, nausea, vomiting, hypertension, and haematuria. Serious adverse reactions occurred in 25% of ERLYAND -treated patients and 23% in patients receiving placebo. The most common serious adverse reactions (≥2%) were fracture (3%) in the ERLYAND arm and urinary retention (4%) in the placebo arm.

Table 1 shows adverse reactions commonly (≥1/100 to <1/10) occurring in ERLYAND-treated patients in TITAN and SPARTAN that occurred with a ≥2% absolute increase in frequency
compared to placebo. Table 2 shows laboratory abnormalities that occurred in ≥15% of patients, and more frequently (>5%) in the ERLYAND arm compared to placebo.

Table 1: Adverse reactions in clinical studies that commonly occurred in ERLYAND-treated patients, and with at least a 2% absolute increase in frequency compared to placebo.

<table>
<thead>
<tr>
<th>System/Organ Class</th>
<th>Adverse reaction</th>
<th>ERLYAND N=1327</th>
<th>Placebo N=925</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grades %</td>
<td>Grade 3-4 %</td>
<td>All Grades %</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Fatigue¹,²</td>
<td>26</td>
<td>1</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Hypertension</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Hot flush²</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>Ischaemic cardiac events³</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Skin rash⁴</td>
<td>26</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Pruritus²</td>
<td>8</td>
<td>0.2</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Diarrhoea</td>
<td>16</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>Nausea</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dysgeusia</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Ischaemic cerebrovascular disorders⁹</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Seizure</td>
<td>0.4</td>
<td>0.1</td>
</tr>
<tr>
<td>Injury, poisoning and procedural complications</td>
<td>Fall²</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Fracture³</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>Arthralgia²</td>
<td>17</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>Muscle spasm</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Investigations</td>
<td>Weight decreased²</td>
<td>13</td>
<td>1</td>
</tr>
<tr>
<td>Endocrine disorders</td>
<td>Hypothyroidism⁶</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite⁷</td>
<td>12</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>Peripheral oedema⁸</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Hypercholesterolemia</td>
<td>6</td>
<td>0.2</td>
</tr>
<tr>
<td></td>
<td>Hypertriglyceridemia</td>
<td>4</td>
<td>0.8</td>
</tr>
</tbody>
</table>
Includes fatigue and asthenia

Per the Common Terminology Criteria for Adverse Reactions (CTCAE), the highest severity for these events is Grade 3

Includes angina pectoris, angina unstable, myocardial infarction, acute myocardial infarction, coronary artery occlusion, coronary artery stenosis, acute coronary syndrome, arteriosclerosis coronary artery, cardiac stress test abnormal, troponin increased, myocardial ischaemia.

Includes rash, rash maculo-papular, rash generalised, urticaria, rash pruritic, rash macular, conjunctivitis, erythema multiforme, rash papular, skin exfoliation, genital rash, rash erythematous, stomatitis, drug eruption, mouth ulceration, rash pustular, blister, papule, pemphigoid, skin erosion, dermatitis, and rash vesicular


Includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine decreased, autoimmune thyroiditis, thyroxine free decreased, tri-iodothyronine decreased

Includes peripheral oedema, generalised oedema, oedema, oedema genital, penile oedema, peripheral swelling, scrotal oedema, lymphoedema, swelling, and localised oedema

Includes transient ischaemic attack, cerebrovascular accident, cerebrovascular disorder, ischaemic stroke, carotid arteriosclerosis, carotid artery stenosis, hemiparesis, lacunar infarction, lacunar stroke, thrombotic cerebral infarction, vascular encephalopathy, cerebellar infarction, cerebral infarction, and cerebral ischemia. Addition of adverse reaction was based on data of the final analysis for the SPARTAN study with a median exposure of 32.9 months for ERLYAND and 11.5 months for placebo.

Additional clinically significant adverse reactions occurring in at least 2% of patients treated with ERLYAND in the SPARTAN study included:

- Depression – 3.9% versus 2.0% on placebo (includes depression, major depression and suicidal ideation).
- Heart failure – 2.2% versus 1.0% on placebo.

Table 2: Laboratory abnormalities occurring in ≥15% of ERLYAND-treated patients and at a higher incidence than placebo (between arm difference >5% all grades) in SPARTAN.

<table>
<thead>
<tr>
<th>Laboratory Abnormality</th>
<th>ERLYAND All Grades</th>
<th>ERLYAND Grades 3-4</th>
<th>Placebo All Grades</th>
<th>Placebo Grades 3-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaemia</td>
<td>70</td>
<td>0.4</td>
<td>64</td>
<td>0.5</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>47</td>
<td>0.3</td>
<td>29</td>
<td>0.0</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>41</td>
<td>2.2</td>
<td>21</td>
<td>2.0</td>
</tr>
<tr>
<td>Hypercholesterolaemia¹</td>
<td>76</td>
<td>0.1</td>
<td>46</td>
<td>0.0</td>
</tr>
<tr>
<td>Hyperglycaemia¹</td>
<td>70</td>
<td>2.0</td>
<td>59</td>
<td>1.0</td>
</tr>
<tr>
<td>Hypertriglyceridaemia¹</td>
<td>67</td>
<td>2.0</td>
<td>49</td>
<td>0.8</td>
</tr>
<tr>
<td>Hyperkalaemia</td>
<td>32</td>
<td>2.0</td>
<td>22</td>
<td>0.5</td>
</tr>
</tbody>
</table>

¹ Does not reflect fasting values

White blood cell count decrease and hypertriglyceridaemia were also more common in the ERLYAND arm compared to placebo in the TITAN study.
Description of selected adverse reactions

Ischaemic cardiovascular events

In a randomised study in patients with nmCRPC (SPARTAN), ischaemic cardiovascular events occurred in 4% of patients treated with ERLYAND and 3% of patients treated with placebo. In a randomised study in patients with mCSPC (TITAN), ischaemic cardiovascular events occurred in 4% of patients treated with ERLYAND and 2% of patients treated with placebo. Across the SPARTAN and TITAN studies, 6 patients (0.5%) treated with ERLYAND and 2 patients (0.2%) treated with placebo died from an ischaemic cardiovascular event. Patients with current evidence of unstable angina, myocardial infarction, or congestive heart failure within 6 months of randomisation were excluded from the SPARTAN and TITAN studies.

See section 4.4 Special warnings and precautions for use.

Fractures

In a randomised study in patients with nmCRPC (SPARTAN), fractures occurred in 12% of patients treated with ERLYAND and in 7% of patients treated with placebo. Grade 3-4 fractures occurred in 3% of patients treated with ERLYAND and in 1% of patients treated with placebo. The median time to onset of fracture was 314 days (range: 20 to 953 days) for patients treated with ERLYAND.

In a randomised study in patients with mCSPC (TITAN), fractures occurred in 9% of patients treated with ERLYAND and in 6% of patients treated with placebo. Grade 3-4 fractures were similar in both arms at 2%. The median time to onset of fracture was 56 days (range: 2 to 111 days) for patients treated with ERLYAND.

Routine bone density assessment and treatment of osteoporosis with bone-targeted agents were not performed in the SPARTAN or TITAN studies.

See section 4.4 Special warnings and precautions for use.

Falls

In a randomised study in patients with nmCRPC (SPARTAN), falls were reported for 16% of subjects treated with ERLYAND versus 9% of subjects treated with placebo, and were not associated with loss of consciousness or seizure. Falls in patients receiving ERLYAND with androgen deprivation therapy were more frequent in the elderly, occurring across the SPARTAN and TITAN studies in 8% of patients younger than 65 years, 10% of patients 65-74 years, and 19% of patients 75 years or older.

In a randomised study in patients with mCSPC (TITAN), rates of falls were similar between the ERLYAND arm (7.4%) and placebo arm (7.0%).

See section 4.4 Special warnings and precautions for use.

Seizure

In two randomised studies (SPARTAN and TITAN), five patients (0.4%) treated with ERLYAND and one patient (0.1%) treated with placebo experienced a seizure. Seizure occurred from 159 to 650 days after initiation of ERLYAND. Patients with a history of seizure, with predisposing factors for seizure, or receiving drugs known to decrease seizure threshold or induce seizures were excluded from both studies.

See section 4.4 Special warnings and precautions for use.

Hypothyroidism

In the combined data of two randomised, placebo-controlled studies (SPARTAN and TITAN), hypothyroidism was reported for 8% of subjects treated with ERLYAND and 2% of subjects treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months. The median onset was Day 113. There were no grade 3 or 4 adverse reactions.
In patients who were already receiving thyroid replacement therapy, hypothyroidism occurred in 30% of subjects in the apalutamide arm and in 3% of subjects in the placebo arm. In subjects not previously receiving thyroid replacement therapy, hypothyroidism occurred in 7% of subjects treated with apalutamide and in 2% of subjects treated with placebo.

Thyroid replacement therapy was initiated in 7% of patients treated with ERLYAND. In patients who discontinued ERLYAND and had a reported event of hypothyroidism (n=14), the event resolved in 5 patients (36%). In patients who discontinued ERLYAND and had increased laboratory values for TSH (>5.5 mIU/L) (n=45), TSH levels returned to normal in 27 patients (60%).

See sections 4.4 Special warnings and precautions for use and 4.5 Effect of ERLYAND on drug metabolising enzymes).

**Skin Rash**

In the combined data of two randomised, placebo-controlled clinical studies (SPARTAN and TITAN), skin rash associated with ERLYAND was most commonly described as macular or maculo-papular. Adverse reactions of skin rash were reported for 26% of subjects treated with ERLYAND versus 8% of subjects treated with placebo. Grade 3 skin rashes (defined as covering >30% body surface area [BSA]) were reported with ERLYAND treatment (6%) versus placebo (0.5%). Toxic epidermal necrolysis (TEN)/Stevens-Johnson syndrome (SJS) were not seen in these trials (n=1327), but cases consistent with severe cutaneous adverse reactions have been reported post-marketing.

The onset of skin rash occurred at a median of 83 days of ERLYAND treatment and resolved in 78% of patients, within a median of 78 days from onset (range: 2 to 709 days). Rash was commonly managed with oral antihistamines, topical corticosteroids and 19% of subjects received systemic corticosteroids. Rash led to dose interruption in 28%, dose reduction in 14% and treatment discontinuation in 7% of cases. Of the patients who had dose interruption, 59% experienced recurrence of rash upon reintroduction of ERLYAND.

**Post-marketing data**

Adverse events identified during post-marketing experience are presented below with frequency category estimated from spontaneous reporting rates. The frequencies are provided according to the following convention:

- **Very common**: ≥ 1/10
- **Common**: ≥ 1/100 and < 1/10
- **Uncommon**: ≥ 1/1,000 and < 1/100
- **Rare**: ≥ 1/10,000 and < 1/1,000
- **Very rare**: < 1/10,000
- **Not known**: Cannot be estimated from the available data

**Metabolism and nutrition disorders**

- Decreased appetite: Uncommon

**Respiratory, thoracic and mediastinal disorders**

- Interstitial lung disease: Not known

**Skin and subcutaneous tissue disorders**
Toxic epidermal necrolysis\(^a\) Rare

\(^a\) The adverse reaction was not identified from clinical trials

**Reporting suspected adverse reactions**


**4.9 OVERDOSE**

**Treatment**

There is no known specific antidote for apalutamide overdose. In the event of an overdose, stop ERLYAND, undertake general supportive measures until clinical toxicity has been diminished or resolved. For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 PHARMACODYNAMIC PROPERTIES**

**Mechanism of action**

Apalutamide is an orally administered, Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide prevents AR nuclear translocation, inhibits DNA binding, impedes AR-mediated transcription, and lacks androgen receptor agonist activity in preclinical studies. A major metabolite, N-desmethyl apalutamide, exhibited one-third the *in vitro* activity of apalutamide in an *in vitro* transcriptional reporter assay. In mouse models of prostate cancer, apalutamide administration causes decreased tumour cell proliferation and increased apoptosis leading to tumour growth inhibition and regression.

**Pharmacodynamic effects**

**Effect on GABA\(_A\)-gated chloride channel**

GABA\(_A\) inhibition is an off-target activity of both apalutamide and N-desmethyl apalutamide. This is considered the mechanism for the seizures/convulsions observed at high doses in toxicology studies in animals.

**Effect on QT/QTc interval and cardiac electrophysiology**

Apalutamide and N-desmethyl apalutamide inhibit the hERG K\(^+\) channel with an IC\(_{50}\) below steady-state C\(_{\text{max}}\) at the recommended dose. In a dedicated QT study in men with CRPC administered apalutamide 240 mg once daily plus ADT, based on the longest QTcF change at any time for each patient at steady-state, the mean maximum QTcF change from baseline (ΔQTcF) was 20.2 msec (upper 90% CI bound 23.7 msec). Pharmacokinetic and pharmacodynamic analysis showed a concentration-dependent increase in QTcF with apalutamide and N-desmethyl apalutamide. See section 4.4 Special warnings and precautions for use.

**Clinical trials**

The efficacy of ERLYAND was established in two randomised placebo-controlled multicentre clinical studies of subjects with mCSPC (TITAN) or nmCRPC (SPARTAN). All subjects in these studies received concomitant GnRH analogue or had prior bilateral orchiectomy.
**TITAN: metastatic castration-sensitive prostate cancer (mCSPC)**

TITAN (56021927PCR3002) was a randomised, double-blind, placebo-controlled, multinational, multicentre clinical trial in which 1052 subjects with mCSPC were randomised (1:1) to receive either ERLYAND orally at a dose of 240 mg once daily (N = 525) or placebo once daily (N = 527). All subjects in the TITAN trial received concomitant GnRH analogue or had prior bilateral orchiectomy. Subjects were stratified by Gleason score at diagnosis, prior docetaxel use, and region of the world. Subjects with both high- and low-volume mCSPC were eligible for the study. High volume of disease was defined as metastases involving the viscera with 1 bone lesion or the presence of 4 or more bone lesions, at least 1 of which must be in a bony structure beyond the vertebral column and pelvic bones.

The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 68 years (range 43-94) and 23% of subjects were 75 years of age or older. The racial distribution was 68% Caucasian, 22% Asian, and 2% Black. Sixty-three percent of subjects had high-volume disease and 37% had low-volume disease. Sixteen percent of subjects had prior surgery, radiotherapy of the prostate or both. A majority of subjects had a Gleason score of 8 or higher (67%). Sixty-eight percent of subjects received prior treatment with an anti-androgen (bicalutamide, flutamide, or nilutamide). All subjects except one in the placebo group, had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at study entry.

The major efficacy outcome measures of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Radiographic progression-free survival was based on investigator assessment and was defined as time from randomisation to radiographic disease progression or death. Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease.

A statistically significant improvement in OS and rPFS was demonstrated in subjects randomised to receive ERLYAND compared with subjects randomised to receive placebo. The results for OS are based upon a prespecified interim efficacy analysis. Efficacy results of TITAN are summarised in Table 3 and Figures 1 and 2.

**Table 3: Summary of efficacy results – intent-to-treat mCSPC population (TITAN)**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ERLYAND N=525</th>
<th>Placebo N=527</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths (%)</td>
<td>83 (16%)</td>
<td>117 (22%)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>NE (NE, NE)</td>
<td>NE (NE, NE)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.67 (0.51, 0.89)</td>
<td>0.0053</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Radiographic progression-free survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease progression or death (%)</td>
<td>134 (26%)</td>
<td>231 (44%)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>NE (NE, NE)</td>
<td>22.1 (18, 33)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.48 (0.39, 0.60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>p-value&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Hazard ratio is from stratified proportional hazards model. Hazard ratio <1 favour active treatment.

<sup>b</sup> p-value is from the log-rank test stratified by Gleason score at diagnosis (≤7 vs. >7), Region (NA/EU vs. Other Countries) and Prior docetaxel use (Yes vs. No).

NE=Not Estimable

Consistent improvement in rPFS and OS was observed between subgroups based on disease volume (high vs low) and Gleason score at diagnosis (≤7 vs. >7). Consistent rPFS was also seen between subgroups based on prior docetaxel use (yes or no).

Treatment with ERLYAND statistically significantly delayed the initiation of cytotoxic chemotherapy (HR = 0.39, CI = 0.27, 0.56; p < 0.0001).
Figure 1: Kaplan-Meier plot of overall survival (OS); intent-to-treat mCSPC population (TITAN)

Subjects at risk:
- Placebo: 527 524 509 502 473 456 387 263 262 142 59 16 3 0
- Apalutamide: 525 519 513 500 490 467 410 289 165 60 14 3 0

Figure 2: Kaplan-Meier plot of radiographic progression-free survival (rPFS); intent-to-treat mCSPC population (TITAN)

Subjects at risk:
- Placebo: 527 488 437 381 325 240 229 140 57 14 3 1 0
- Apalutamide: 525 488 469 434 389 320 313 194 89 21 2 1 0
SPARTAN: non-metastatic, castration-resistant prostate cancer (nmCRPC)

SPARTAN (Study ARN 509-003) was a multicentre, double-blind, randomised, placebo-controlled clinical trial in which 1207 subjects with nmCRPC were randomised 2:1 to receive either ERLYAND orally at a dose of 240 mg once daily (n=806) or placebo once daily (n=401). All patients received a concomitant gonadotropin-releasing hormone (GnRH) analogue, or had a bilateral orchectomy. Patients were required to have a Prostate Specific Antigen (PSA) Doubling Time (PSADT) ≤ 10 months and confirmation of non-metastatic disease by blinded independent central review (BICR). Patients with pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation could enter the SPARTAN study. Patients were stratified by PSADT (>6 months vs ≤ 6 months), the use of bone-sparing agents, and presence of locoregional disease. Systemic corticosteroids were not allowed at study entry. PSA results were blinded and were not used for treatment discontinuation. Subjects randomised to either arm discontinued treatment for disease progression confirmed by BICR, initiation of new treatment, unacceptable toxicity or withdrawal. Upon BICR-confirmed development of distant metastatic disease, subjects were offered abiraterone acetate as an option for the first subsequent treatment after study treatment discontinuation.

The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 74 years (range 48-97) and 26% of subjects were 80 years of age or older. The racial distribution was 66% Caucasian, 5.6% Black, 12% Asian, and 0.2% Other. Seventy-seven percent (77%) of subjects in both treatment arms had prior surgery or radiotherapy of the prostate. A majority of subjects had a Gleason score of 7 or higher (81%). Fifteen percent (15%) of subjects had <2 cm pelvic lymph nodes at study entry. In the SPARTAN study, metastases were detected by technetium-99m bone scan, CT or MRI of the chest, abdomen and pelvis. Seventy-three percent (73%) of subjects had received prior treatment with a first-generation anti-androgen; 69% of subjects had received bicalutamide and 10% of subjects had received flutamide. All subjects enrolled had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status score of 0 or 1 at study entry. Among the patients who discontinued study treatment (N = 279 for placebo and N = 314 for ERLYAND), a greater proportion (80%) of patients treated with placebo received subsequent therapy compared to patients treated with ERLYAND (56%). Locoregional-only progression occurred in 2% of patients overall.

The primary efficacy outcome was metastasis-free survival (MFS), defined as the time from randomisation to the time of first evidence of BICR-confirmed distant metastasis (defined as new bone or soft tissue lesions or enlarged lymph nodes above the iliac bifurcation) or death due to any cause, whichever occurred first. Additional efficacy endpoints were time to metastasis (TTM), progression-free survival (PFS) which also includes locoregional progression, and overall survival (OS).

A statistically significant improvement in MFS was demonstrated in patients randomised to receive ERLYAND compared with patients randomised to receive placebo. Consistent results were observed across patient subgroups including PSADT (≤ 6 months or > 6 months), use of a prior bone-sparing agent (yes or no), and locoregional disease (N0 or N1). The primary efficacy outcome was supported by statistically significant improvements in TTM, PFS, and time to symptomatic progression. Overall survival (OS) data were not mature at the time of final MFS analysis (24% of the required number of events).

Efficacy results of SPARTAN are summarised in Table 4 and Figure 3.
Table 4: Summary of efficacy results – intent-to-treat nmCRPC population (SPARTAN)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ERLYAND (n=806) Median (months)</th>
<th>Placebo (n=401) Median (months)</th>
<th>HR (95% CI)</th>
<th>p value¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metastasis-free survival (MFS)</td>
<td>40.5</td>
<td>16.2</td>
<td>0.28 (0.23-0.35)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Time to metastasis (TTM)</td>
<td>40.5</td>
<td>16.6</td>
<td>0.27 (0.22-0.34)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Progression-free Survival (PFS)</td>
<td>40.5</td>
<td>14.7</td>
<td>0.29 (0.24-0.36)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

NR = Not reached
¹ p value from stratified log-rank test

Figure 3: Kaplan-Meier plot of metastasis-free survival (MFS); intent-to-treat nmCRPC population (SPARTAN)

5.2 PHARMACOKINETIC PROPERTIES

Apalutamide pharmacokinetic parameters are presented as the mean (coefficient of variation; CV%) unless otherwise specified. Following repeat once-daily dosing, apalutamide exposure (C_{max} and AUC) increased in a dose-proportional manner across the dose range of 30 mg to 480 mg (0.125 to 2 times the recommended dosage). Following administration of the recommended dosage, apalutamide steady state was achieved after 4 weeks and the mean accumulation ratio was approximately 5-fold. At steady-state, apalutamide C_{max} was 6 µg/mL (28%) and AUC was 100 µg.h/mL (32%). Daily fluctuations in apalutamide plasma concentrations were low, with mean peak-to-trough ratio of 1.63. An increase in apparent clearance (CL/F) was observed with repeat dosing, likely due to induction of apalutamide’s own metabolism.

At steady-state, the major active metabolite (N-desmethyl apalutamide) C_{max} and was 5.9 µg/mL (18%) and AUC was 124 µg.h/mL (19%). N-desmethyl apalutamide is characterised by a flat concentration-time profile at steady-state with a mean peak-to-trough ratio of 1.27. The AUC
metabolite/parent drug ratio for N-desmethyl apalutamide following repeat-dose administration was about 1.3 (21%). Based on systemic exposure, relative potency, and pharmacokinetic properties, N-desmethyl apalutamide likely contributes to the clinical activity of apalutamide.

**Absorption**

Mean absolute oral bioavailability is approximately 100%. Median time to achieve peak plasma concentration ($t_{max}$) was 2 hours (range: 1 to 5 hours).

Administration of apalutamide to healthy subjects under fasting conditions and with a high-fat meal resulted in no clinically relevant changes in $C_{max}$ and AUC. Median time to reach $t_{max}$ was delayed about 2 hours with food.

**Distribution**

The mean apparent volume of distribution at steady-state of apalutamide is about 276 L (greater than the volume of total body water, indicative of extensive extravascular distribution).

Apalutamide is 96% (and N-desmethyl apalutamide is 95%) bound to plasma proteins, with no concentration dependency. Studies in rodents and dogs indicate that apalutamide and N-desmethyl apalutamide can cross the blood brain barrier.

**Metabolism**

Metabolism is the main route of elimination of apalutamide. It is metabolised primarily by CYP2C8 and CYP3A4 to form N-desmethyl apalutamide. Apalutamide and N-desmethyl apalutamide are further metabolised by carboxylesterase to form an inactive carboxylic acid metabolite. The contribution of CYP2C8 and CYP3A4 in the metabolism of apalutamide is estimated to be 58% and 13% following single dose but changes to 40% and 37%, respectively at steady-state.

Apalutamide (45%), N-desmethyl apalutamide (44%), and an inactive carboxylic acid metabolite (3%) represented most of the total $^{14}$C-AUC following a single oral administration of $^{14}$C-labeled apalutamide 240 mg.

**Excretion**

Up to 70 days following a single oral administration of radiolabeled apalutamide, 65% of the dose was recovered in urine (1.2% of dose as unchanged apalutamide and 2.7% as N-desmethyl apalutamide) and 24% was recovered in faeces (1.5% of dose as unchanged apalutamide and 2% as N-desmethyl apalutamide).

The CL/F of apalutamide is 1.3 L/h after single dosing and increases to 2.0 L/h at steady-state after once-daily dosing. The mean effective half-life for apalutamide in subjects is about 3 days at steady-state.

**Special populations**

No clinically significant differences in the pharmacokinetics of apalutamide or N-desmethyl apalutamide were observed based on age (18-94 years), race (Black, non-Japanese Asian, Japanese), mild to moderate renal impairment (eGFR 30-89 mL/min/1.73m², estimated by the modification of diet in renal disease [MDRD] equation) or mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment.

The effect of severe renal impairment or end stage renal disease (eGFR ≤29 mL/min/1.73m²) or severe hepatic impairment (Child-Pugh Class C) on apalutamide pharmacokinetics is unknown.
5.3 PRECLINICAL SAFETY DATA

Genotoxicity
Apalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either in vitro chromosome aberration test in human lymphocytes, the in vivo rat micronucleus assay or the in vivo rat Comet assay.

Carcinogenicity
Long-term animal studies have not been conducted to evaluate the carcinogenic potential of apalutamide.

6. PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Tablet core
Colloidal anhydrous silica
Croscarmellose sodium
Hypermellose acetate succinate
Magnesium stearate
Microcrystalline cellulose
Silicified microcrystalline cellulose

Film-coat
Opadry® II 85F210036 Green

6.2 INCOMPATIBILITIES
Not applicable.

6.3 SHELF LIFE
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store below 30°C. Keep out of the sight and reach of children. Protect from light and moisture.

6.5 NATURE AND CONTENTS OF CONTAINER
ERLYAND is available in opaque, high-density polyethylene bottles with child-resistant polypropylene closure and induction seal liner. Each bottle contains 120 tablets and a desiccant.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.
6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure

**CAS number**

956104-40-8

The drug substance has a dissociation constant pKa of 9.7 (acidic carboxamide moiety) and is practically insoluble in aqueous media over a wide range of pH values and practically insoluble to very soluble in organic solvents. The Log P at 20°C between 1-octanol and an aqueous buffered solution (pH 7.0) is 2.89. The Log D at 20°C between 1-octanol and aqueous buffered solutions (pH 1.0, 4.0 and 7.0) is 2.86, 2.80 and 2.89 respectively. Molecular formula: C_{21}H_{15}F_{4}N_{5}O_{2}S. Molecular weight: 477.43.

7. MEDICINE SCHEDULE (POISONS STANDARD)

Prescription Only Medicine

8. SPONSOR

JANSSEN-CILAG Pty Ltd
1-5 Khartoum Rd Macquarie Park NSW 2113 Australia
Telephone: 1800 226 334

NZ Office: Auckland New Zealand

9. DATE OF FIRST APPROVAL (ARTG ENTRY)

05 July 2018

10. DATE OF REVISION

22 October 2020

Summary table of changes

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>1. Addition of new indication in castrate sensitive and metastatic. Editorial change to the existing approved indication wording</td>
</tr>
<tr>
<td>4.4</td>
<td>2. Updated Precautions subsection on Ischaemic heart disease and ischaemic cerebrovascular disorders</td>
</tr>
<tr>
<td>4.5</td>
<td>3. Introduction of new text “Gonadotropin-releasing hormone (GnRH) analogue”</td>
</tr>
</tbody>
</table>
### 4.8

4. Added Interstitial lung disease as adverse effect observed in post marketing experience. Also editorial changes underneath Table 1. Also added decreased appetite and toxic epidermal necrolysis and ischaemic cerebrovascular disorders.

### 5.1

5. Updated Clinical Trials section to include the TITAN castrate sensitive metastatic prostate cancer study results.